Zealand Pharma compound in phase II study  

2006.04.11
Sanofi-Aventis has initiated a phase II dose study for ZP10, the first product of Danish biopharmaceutical company Zealand Pharma, for the treatment of Type 2 diabetes

Sanofi-Aventis has initiated a phase II dose study for ZP10, the first product of Danish biopharmaceutical company Zealand Pharma, for the treatment of Type 2 diabetes. 500 diabetic patients will be included in the study which will be conducted in the US. Zealand Pharma expects the compound to enter phase III in 2007.

Eva Steiness, director of Zealand Pharma comments: "We have now initiated the last phase II study to find the final dose, and it is expected to be finished in 2007. Then the plan is to start phase III trials." ZP10 is a glucagon-like peptide 1, or GLP-1, receptor agonist developed for subcutaneous injection treatment of Type 2 Diabetes and incorporates Zealand Pharma's Structure Inducing Probe technology.

Copenhagen based Zealand Pharma was founded in 1998. The company focuses on discovery and development of novel peptide based drugs. Zealand's pipeline includes three compounds currently in clinical development, two of which have been out-licensed to major pharmaceutical companies. Investors in Zealand Pharma include BankInvest, LD Pensions, CDC Entreprises Innovation, AGF Private Equity and Life Sciences Partners.

Link > Zealand Pharma 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×